ClinicalTrials.gg

Hyperglycemia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 801 studies for Hyperglycemia across more than 10 countries. 115 are recruiting or about to start. 311 of them are mainly about Hyperglycemia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its narrower condition Glucose Intolerance too: 1,560 studies, 226 open.

ClinicalTrials.gov finds 1,791 studies for Hyperglycemia. How that becomes 800 here

This page counts the studies the registry files under Hyperglycemia, and those it files under no condition that list Hyperglycemiathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,791Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −752Filed under a narrower condition, counted on its own pageGlucose Intolerance 752
  3. −36List Hyperglycemia as a condition, but the registry did not file them under itMost often written as “Stress Hyperglycemia” (5), “Hyperglycemia Due to Type 2 Diabetes Mellitus” (5), and “Hyperglycemia Stress” (4). The registry filed them under other conditions only, most often Diabetes Mellitus, Type 2 (9) and Diabetes Mellitus (8).
  4. −203Match it another way140 name it in the title, 22 in a keyword, and 41 by a synonym or other text the search reads.
  5. 800The count on this page32 of them list Hyperglycemia in their own words; the registry filed them under no condition.

Status

Completed
524
Status unknown
74
Recruiting
71
Terminated
41
Not yet recruiting
35
Withdrawn
23

Phase

Phase 4
89
Phase 3
57
Phase 2
56
Phase 1
45
Early Phase 1
13

Where

United States
316
Canada
46
United Kingdom
33
China
32
Denmark
27
Mexico
26

Who develops what

Add Hyperglycemia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 1 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Eli Lilly and Sino Biopharmaceutical here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
insulin degludecRecent, limited
Evidence
  • NCT07215312 · Eli Lilly and Company · Phase 2 · live · comparator · “Degludec” · registered Oct 2025
Novo Nordisk A/S93% of its industry studiesUS: Novo Nordisk A/S (FDA 2015)EU: Novo Nordisk A/S (EMA 2013)11 study
MetforminEarlier onlyPhase 4 trial recorded
Evidence
  • NCT04899349 · Novartis · Phase 2 · background · “Metformin XR” · registered May 2021
  • NCT02060383 · Novartis · Phase 4 · background · “Metformin” · registered Feb 2014
  • NCT02002221 · Novartis · Phase 4 · background · “Metformin” · registered Nov 2013
  • NCT00856284 · Takeda · Phase 3 · background · “Metformin” · registered Mar 2009
  • NCT00763451 · Sanofi · Phase 3 · background · “Metformin” · registered Sep 2008
AstraZeneca9% of its industry studies00 studies
PioglitazoneEarlier only
Evidence
  • NCT01280695 · Metabolic Solutions Development Company · Phase 2 · comparator · “Pioglitazone” · registered Jan 2011
  • NCT01230749 · Johnson & Johnson · Phase 2 · comparator · “Pioglitazone 30 mg” · registered Oct 2010
Takeda45% of its industry studiesUS: off-patent, 9 generics marketedEU: off-patent, 2 generics authorized00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.LY3938577 · Eli Lilly and Company · Phase 2 registry mapping only+ LY3938577 vs insulin degludecNCT07215312 A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin — primary endpoint: Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis) · 100 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hyperglycemia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here GLP-1 receptor agonists 2 open · DPP-4 inhibitors 1 open · SGLT2 inhibitors 10 · Corticosteroids 4

Coming up

43studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 71 Hyperglycemia studies recruiting now, 42 (59%) set no upper age limit and 23 (32%) stop at 75 or younger. 10 (14%) take children under 18. 7 (10%) are for women only and 2 (3%) for men only; 15 (21%) take healthy volunteers.

Recruiting studies that take each age, of 71
AgeWomenMen
104 (6%)4 (6%)
1855 (77%)50 (70%)
3058 (82%)53 (75%)
4058 (82%)53 (75%)
5056 (79%)53 (75%)
6555 (77%)54 (76%)
7547 (66%)46 (65%)
8543 (61%)42 (59%)

Across all 801 studies, recruiting or not: 47% stop at 75 or younger and 33% at 65; 12% take children; 4% are for women only and 3% for men only; 29% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hyperglycemia studies take

Of 24 phase 4 interventional studies under Hyperglycemia, half reached primary completion within 33 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 115 mo5–26 · 17 studies——
Phase 433 mo11–48 · 24 studies——
Interventional, no phase14 mo7–27 · 225 studies—14 mo9–27 · 208 studies
Observational28 mo15–42 · 65 studies—30 mo15–43 · 63 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 801. Browse all 801 → or search them.